Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma

Daratumumab, a CD38-targeting monoclonal antibody, has significantly improved survival rates in multiple myeloma (MM), yet patients who progress on Daratumumab have dismal clinical outcomes with an overall median of less than 10 months. While emerging novel modalities have shown promising results, t...

Full description

Bibliographic Details
Main Authors: Lakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, Reid D. Landes, Mathew Kottarathara, Yetunde Ogunsesan, Shadiqul Hoque, Angel A. Mitma, Clyde Bailey, Kerri M. Hill, Sharmilan Thanendrarajan, Monica Graziutti, Meera Mohan, Maurizio Zangari, Frits van Rhee, Guido Tricot, Carolina Schinke
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
multiple myeloma
daratumumab
autologous stem cell transplantation
Online Access:https://www.mdpi.com/2072-6694/13/16/4019

Internet

https://www.mdpi.com/2072-6694/13/16/4019

Similar Items